Other: Exposure to methylprednisolone during pregnancy ( DrugBank: Methylprednisolone )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04832269 (ClinicalTrials.gov) | October 19, 2020 | 18/2/2021 | Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour | Effects of a Multiple Sclerosis Relapse Therapy With Methylprednisolone (MP) During Pregnancy on Offspring Cognitive Function, Stress Sensitivity, Behaviour and Functional and Structural Brain Development | Multiple Sclerosis | Other: Exposure to methylprednisolone during pregnancy | Jena University Hospital | Ruhr University of Bochum;Interdisciplinary Center of Clinical Research of the Medical Faculty Jena;Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Recruiting | 8 Years | 18 Years | All | 80 | Germany |